China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China.
Adequate balance sheet and overvalued.
Share Price & News
How has China Pharma Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CPHI's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: CPHI exceeded the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: CPHI exceeded the US Market which returned 10.5% over the past year.
Price Volatility Vs. Market
How volatile is China Pharma Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs China Pharma Holdings's (NYSEMKT:CPHI) 107% Share Price Increase Well Justified?
1 month ago | Simply Wall StEstimating The Intrinsic Value Of China Pharma Holdings, Inc. (NYSEMKT:CPHI)
1 month ago | Simply Wall StIs China Pharma Holdings, Inc. (NYSEMKT:CPHI) Overpaying Its CEO?
Is China Pharma Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: CPHI ($0.53) is trading above our estimate of fair value ($0.44)
Significantly Below Fair Value: CPHI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CPHI is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: CPHI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CPHI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CPHI is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (2.9x).
How is China Pharma Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as China Pharma Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine China Pharma Holdings's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- China Pharma Holdings competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has China Pharma Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPHI is currently unprofitable.
Growing Profit Margin: CPHI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CPHI is unprofitable, but has reduced losses over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare CPHI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPHI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.4%).
Return on Equity
High ROE: CPHI has a negative Return on Equity (-34.91%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is China Pharma Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: CPHI's short term assets ($6.2M) do not cover its short term liabilities ($9.6M).
Long Term Liabilities: CPHI's short term assets ($6.2M) exceed its long term liabilities ($2.9M).
Debt to Equity History and Analysis
Debt Level: CPHI's debt to equity ratio (22.2%) is considered satisfactory.
Reducing Debt: CPHI's debt to equity ratio has increased from 16.8% to 22.2% over the past 5 years.
Inventory Level: CPHI has a high level of physical assets or inventory.
Debt Coverage by Assets: CPHI's debt is covered by short term assets (assets are 1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable CPHI has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: CPHI is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 59.4% per year.
What is China Pharma Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate CPHI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CPHI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPHI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPHI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CPHI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Zhilin Li (66yo)
Ms. Zhilin Li has been the Chief Executive Officer and President of China Pharma Holdings, Inc. since October 19, 2005 and serves as its Interim Chief Financial Officer. Ms. Li is a founder of Helpson Bio- ...
CEO Compensation Analysis
Compensation vs Market: Zhilin's total compensation ($USD241.60K) is below average for companies of similar size in the US market ($USD524.26K).
Compensation vs Earnings: Zhilin's compensation has been consistent with company performance over the past year.
|Independent Director||12yrs||US$16.00k||no data|
|Independent Director||12yrs||US$6.43k||no data|
|Independent Director||12yrs||US$6.43k||no data|
Experienced Board: CPHI's board of directors are seasoned and experienced ( 12 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
China Pharma Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: China Pharma Holdings, Inc.
- Ticker: CPHI
- Exchange: AMEX
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$24.361m
- Shares outstanding: 43.58m
- Website: https://www.chinapharmaholdings.com
Number of Employees
- China Pharma Holdings, Inc.
- No. 17, Jinpan Road
- Second Floor
- Hainan Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CPHI||AMEX (NYSE MKT LLC)||Yes||Common Stock||US||USD||Apr 2002|
|XQJ||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Apr 2002|
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People’s Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People’s Republic of China.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/27 00:25|
|End of Day Share Price||2020/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.